🛡️ Immunogenicity does not compromise outcomes with subcutaneous #infliximab
🔸Anti-drug antibodies (#ADAs) lowered drug levels but not 1-year efficacy or safety
🔸Treatment persistence remained similar regardless of ADA status
Find out more in this UEG Journal article:
👉 bit.ly/3UESgZp